Genmab — November 2019

[Sukkeralf]

I cant see a ASH late breaker from Genmab - so here I guess its more a question on how fierce a competitor might be (ect GSKs BCMA ADC)

[bibob]

Sukker. Maybe Genmab have a surprice for us in Late Breaking . We can hope so.

[E_L]

i think Jefferies is already one of the highest at 1850, so an upgrade would be interesting

[bibob]

Up to 2000 will be welcome.

[E_L]

I did not expect a late braker either, but in their ash press anouncement they stated "Late breaking abstracts are not yet available.", so that makes me curious, why would they say that? But i may be reading to much into that.

[bibob]

Allways look on the bride side E L.

[E_L]

[Sukkeralf]

After interim for futility in amyloidosis "just" said carry on I cant think of anything other than Janssens BCMA/CD3 if thats not too early. Cant remember the criteria for late breaker

[Sukkeralf]

Im a bit disappointed that Janssen havent yet presented any preliminary clinical data on BCMA/CD3 yet

[Sukkeralf]

E L its a bit strange the way Genmab writes that - no need to put focus on late breaker abstracts if you did not have a chance for that

[E_L]

yes, agree. but like you, I wouldn't know what it could be. BCMA/CD3 would definately be nice surprise!

[Sukkeralf]

Otherwise it could be dara in something - AML/MDS maybe

[Bulder]

Would be a bit of a surprise, as LBs are not just ordinary abstracts, but "outstanding studies".

[bibob]

May they keep an abstrct " secret " until LB. ??

[Sukkeralf]

Agree Bulder

[Sukkeralf]

bibob - deadline for late breaker was in october

[Sukkeralf]

So at least not secret to the ASH commitee

[Bulder]

Only 6 abs will be selected.

[Bulder]

bibob, they not only "may", they must keep it as a secret, as data are embargoed until publication.

[Solsen]

Foreløbig ny ATH i dag med 1519 kr